 |
인쇄하기
취소
|
Korean drug Agency OKs local trial of innovative osteoporosis drug
Helixer Co., a local biopharmaceutical company, said on October 26 that it has received approval from the Korean Food and Drug Administration to conduct Phase 3 clinical trial of a drug, PG201, for the treatment of osteoporosis.
The company said the approval comes after successful completion of pre-clinical and clinical studies on PG201 containing 12 herbal ingredients.
"Tests conducted s...
The company said the approval comes after successful completion of pre-clinical and clinical studies on PG201 containing 12 herbal ingredients.
"Tests conducted s...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.